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Abstract
Objective: Carbapenem-resistant Acinetobacter baumannii (CR-AB) is an emerging cause of nosocomial infections
worldwide. Combination therapy may be the only viable option until new antibiotics become available. The objective of this
study is to identify potential antimicrobial combinations against CR-AB isolated from our local hospitals.
Methods: AB isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs
were determined according to CLSI guidelines. All CR-AB isolates were genotyped using a PCR-based method. Clonal
relationship was elucidated. Time-kill studies (TKS) were conducted with polymyxin B, rifampicin and tigecycline alone and
in combination using clinically relevant (achievable) unbound concentrations.
Results: 31 CR AB isolates were identified. They are multidrug-resistant, but are susceptible to polymyxin B. From clonal
typing, 8 clonal groups were identified and 11 isolates exhibited clonal diversity. In single TKS, polymyxin B, rifampicin and
tigecycline alone did not exhibit bactericidal activity at 24 hours. In combination TKS, polymyxin plus rifampicin, polymyxin
B plus tigecycline and tigecycline plus rifampicin exhibited bactericidal killing in 13/31, 9/31 and 7/31 isolates respectively at
24 hours. Within a clonal group, there may be no consensus with the types of antibiotics combinations that could still kill
effectively.
Conclusion: Monotherapy with polymyxin B may not be adequate against polymyxin B susceptible AB isolates. These
findings demonstrate that in-vitro synergy of antibiotic combinations in CR AB may be strain dependant. It may guide us in
choosing a pre-emptive therapy for CR AB infections and warrants further investigations.
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Introduction
Acinetobacter baumannii is a successful pathogen that has evoked
scientific and public interest worldwide.[1] It is increasingly
multidrug-resistant due to its wide repertoire of antimicrobial
resistance mechanisms and its innate ability to acquire new
resistance determinants.[2] As a frequently occurring pathogen
associated with serious nosocomial infections, A. baumannii had
been shown to be associated with unfavourable clinical out-
comes.[3,4]
The antibiotic development pipeline is under pressure from the
alarming spread of antimicrobial resistance and for all practical
purposes is completely dry. Thus, for treatment of these difficult-to-
treat non-fermentative organisms, we are now in the pre-antibiotic
era. Carbapenems, members of a potent broad-spectrum antimi-
crobial class, are increasingly being used as first-line therapy in
institutions where there is a high prevalence of multidrug-resistant
bacterial infections. With the advent of increasing usage and poor
infection control, carbapenem resistance has emerged worldwide
and there has been a surge in recent reports of outbreaks involving
multidrug-resistant A. baumannii that are also carbapenem-resistant
(CR-AB).[5,6] This phenomena has resulted in the revival of the
polymyxins, which are increasingly used as the last line of defence
against such difficult-to-treat infections.
Inevitably, growing reports of polymyxin heteroresistance in
CR-AB and even pan drug-resistant A. baumannii (PDR-AB) have
come to light.[7,8] These evidences had suggested against the use
of polymyxins as monotherapy. Tigecycline is a new glycylcycline
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baumannii isolates. However, its clinical utility has yet to be
demonstrated alone or in combination with other antibiotics.[9]
Other than stringent infection control measures, combination
therapy may be our only current remaining viable therapeutic
option in treating infections caused by such bacteria. Therefore,
the objective of this study was to identify potential bactericidal
antimicrobial combinations against CR-AB in Singapore.
Materials and Methods
Antimicrobial agents
Polymyxin B and rifampicin were obtained from Sigma-Aldrich
(St. Louis, MO). Tigecycline was obtained from Wyeth Pharma-
ceuticals (Pearl River, NY). For polymyxin B, a stock solution in
sterile water was prepared, aliquoted, and stored at 270uC.
Tigecycline in solution was freshly prepared before each experi-
ment. On the other hand, rifampicin was dissolved in dimethyl
sulfoxide and was then serially diluted in sterile water to the
desired final drug concentration. The final dimethyl sulfoxide
concentration had no effect on A. baumannii growth. Prior to each
susceptibility test, an aliquot of the drug was thawed and diluted to
the desired concentrations with Ca-MHB.
Microorganisms and susceptibility testing
Acinetobacter baumannii isolates from the urinary tract, blood and
respiratory tract were collected from five geographically separate
hospitals over a two-year period (2006–2007) by Network for
Antimicrobial Resistance Surveillance (Singapore). These CR-AB
isolates were previously described harbouring the blaOXA-23-like
and blaOXA-51-like carbapenemase genes, with the ISAba1
upstream of the blaOXA-23 gene (results not shown).[10] Genus
identity was initially determined using conventional biochemical
methods and ID-GN cards (Vitek 2, bioMe ´rieux, France) and
confirmed by PCR-based method.[11] Minimum inhibitory
concentrations (MIC) to ampicillin/sulbactam, ciprofloxacin,
gentamicin, imipenem, meropenem, aztreonam, piperacillin/
tazobactam, polymyxin B, tigecycline, ceftazidime, amikacin and
cefepime were obtained by microbroth dilution. MICs to
rifampicin were obtained by a modified broth macrodilution
method as described by the CLSI.[12] CR-AB were defined as
isolates resistant to all tested antibiotics classes except polymyx-
ins.[13] The bacteria were stored at 270uC in ProtectH (Key
Scientific Products, Stamford, TX, USA) storage vials. Fresh
isolates were sub-cultured twice on 5% blood agar plates
(Biomedia-Bloxwich, Malaysia) for 24 h at 35uC prior to each
experiment.
Clonal Relationship Analysis
All study isolates were genotyped using a PCR-based meth-
od.[14] Digital images of the DNA fingerprints were processed
using Gene Profiler 4.05 (Scanalytics, BD Biosciences, USA) and
similarity analysis, distance estimation and cluster analysis using
UPGMA were performed using Treecon software.
Time-kill studies
Time-kill studies were conducted with polymyxin B, rifampicin
and tigecycline alone and in combination using clinically relevant
(achievable) unbound concentrations. Hence, the simulated
steady-state drug concentrations were 2 mg/L (free or unbound
protein fraction) for polymyxin B, rifampicin and tigecycline, with
corresponding maximum intravenous doses of at least 1 million
units of polymyxin B (every 12 hours), 600 mg of rifampicin (every
12 hours) and 100 mg of tigecyline (every 12 hours).[15,16,17]
An overnight culture of the isolate was diluted into pre-warmed
cation-adjusted Mueller Hinton II broth (Ca-MHB) (BBL, BD,
USA) and incubated further at 35uC until reaching log-phase
growth. The bacterial suspension was diluted with Ca-MHB
according to absorbance (at 630 nm); 15 ml of the suspension was
transferred to 50-ml sterile conical flasks, each containing 1 ml of a
drug dilution at 16 times the target concentration. The final
concentration of the bacterial suspension in each flask was
approximately 10
5 CFU/ml (ranging from 1610
5 CFU/ml to
5610
5 CFU/ml).
Flasks were incubated in a shaker water bath at 35uC. Serial
samples of broth were obtained from each flask at 0 (baseline), 2, 4,
8, 12 and 24 hours after incubation. Samples were obtained in
duplicate at each time-point. Extracted broth samples (0.5 ml)
were first centrifuged at 10,000 x g for 15 minutes and then
reconstituted with sterile normal saline to their original volumes in
order to minimize drug carryover. The total bacterial count for
each sample was quantified by depositing serial 10-fold dilutions of
broth samples onto Mueller Hinton agar (MHA) plates (Biomedia,
Bloxwich, Malaysia) using a spiral-plater (Interscience, St Nom La
Breteche, France).
Inoculated plates were incubated in a humidified incubator
(35uC) for 18 to 24 h, bacterial colonies were visually counted, and
the original bacterial density from the original sample was
calculated based on the dilution factor. The lower limit of
detection for the colony counts was 2 log10 CFU/ml.
Pharmacodynamic endpoints
Bactericidal activity (primary endpoint) was defined as a $3
log10 CFU/ml decrease in the colony count from the initial
inoculum at 24 hours. Synergy (secondary endpoint) was defined
as a $2 log10 CFU/ml decrease in the colony count by the drug
combination when compared with its most active constituent and
a $2 log10 CFU/ml decrease from the initial inoculum at
24 hours while indifference was defined as a ,2 log10 CFU/ml
change at 24 hours by the combination compared with that by the
most active single agent.[18]
Results
Susceptibility
Thirty-one CR-AB isolates were identified. All isolates were
resistant to meropenem, imipenem, ampicillin/sulbactam, cipro-
floxacin, gentamicin, aztreonam, piperacillin/tazobactam, ceftaz-
idime, cefepime and amikacin. (data not shown) But they were
susceptible to polymyxin B (MIC range 0.5–2 mg/L). There are
no CLSI susceptibility breakpoints for rifampicin and tigecycline
against A. baumannii. The MICs of rifampicin and tigecycline
ranged from 1–$64 mg/L and 0.5–$32 mg/L respectively
(Table 1).
Clonal Relationship Analysis
Applying a similarity index of 90% to PCR typing results, 8
clonal clusters were identified consisting of groups of 2 or 3 isolates
for each cluster. Eleven remaining isolates showed greater clonal
diversity (Figure 1).
Time-kill studies
In time-kill studies, polymyxin B alone generally demonstrated
indifferent activity in 26 out of 31 CR AB strains where there were
,2 log10 CFU/ml decrease between the initial inocula and the
24 hr time-point in the colony counts. Five out of 31 strains
showed an increase in bacteria density and a higher bacteria
concentration was observed at 24 hours (,8 log10 CFU/ml).
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in bacterial burden respectively. The average increase in CFU/ml
from baseline was greater than 2 log10 CFU/ml at 24 hours for all
strains except for AB 17 (average 1.5 log10 reduction from
baseline) against rifampicin and tigecycline alone and AB 32
(average 1.9 log10 reduction from baseline) against tigecycline
alone (Table 2).
For the various antibiotic combinations, polymyxin B plus
rifampicin achieved the highest percentage of bactericidal activity
in 13 out of 31 isolates (41.9%) and indifferent activity against the
rest of the isolates; polymyxin B plus tigecycline achieved
bactericidal activity in 9 out of 31 isolates (29.0%); whereas
tigecycline plus rifampicin achieved the lowest percentage of
bactericidal activity in 7 out of 31 isolates (22.6%) (Table 3). None
of the antibiotics combinations demonstrated bactericidal activity
against 14 out of 31 strains tested.
Of these 14 isolates, 8 elicited indifferent activity when
combination antibiotics were used. Using synergy as the secondary
endpoint to compare the activity of the antibiotic combinations,
tigecycline plus rifampicin was synergistic in 3 isolates while all
three antibiotic combinations showed synergistic activity against 1
isolate (AB 28). Against the remaining 2 isolates, polymyxin B
alone is more effective (i.e. with the lowest bacteria burden at
24 hours compared against the baseline inocula when compared
to all combination antibiotics.
Comparing the results with respect to the 8 major clonal groups
of isolates, the results were in agreement for 2 clonal groups (isolates
91, 97 & 98; isolates 14101, 13631 & 48038) for all antibiotic
combinations while 4 clonal groups had only 66% similarity for all
combinations. The remaining 2 groups showed conflicting results
where there is only 33% similarity in the results (Table 4).
Discussion
Infections caused by carbapenem-resistant A. baumannii present
challenges to clinicians where they are left with practically no
rational choice of antimicrobial treatment. As a result, there are
Table 1. Susceptibilities of 31 A. baumannii isolates.
Susceptibility (%)
Antibiotics
MIC50
(mg/L)
MIC90
(mg/L)
Range
(mg/L) RI S
Polymyxin B 1 2 0.5–2 – – 100
Rifampicin 6 $64 1–$64 – – –
Tigecycline 4 $32 0.5–$32 – – –
doi:10.1371/journal.pone.0018485.t001
Figure 1. Phylogenetic Tree Diagram showing * clonal groups. A yellow oval, denote a clonal group after applying a similarity index of 90%
to PCR typing results.
doi:10.1371/journal.pone.0018485.g001
Combination Therapy for Carbapenem-Resistant AB
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18485growing reports of such infections for which no therapeutic option
exists.[13,19] Combination therapy for the treatment of CR-AB
organisms has increasingly been used although clinical trials of
antibiotic combinations showing enhanced activity are extremely
rare. Therefore, any antibiotic combinations that yield some
success in-vitro are the only potential solution in these clinically
stuck situations.
Unlike the conventional rationale when combining 2 agents is to
enhance the activity of either agent through the achievement of a
synergistic effect, an additional objective is to help to attain an
enhanced pharmacodynamic effect that can potentially curb the
emergence of further resistance.[20] As the observed CR AB
phenotype can be mediated by several molecular mechanisms of
resistance, an antibiotic combination that has been previously
elucidated against a particular organism may not always be
effective for another patient having the same infection. Within a
clonal group, there may be no consensus with the types of
antibiotics combinations that could still kill effectively. As AB picks
up resistance determinants with great ease, one speculation could
be that different antibiotic resistant mechanisms, which may be
up-regulated or acquired, to a different extent during different
antibiotics exposure, could possibly be found in related isolates. An
additional caution is then that combination testing data could not
reliably be applied to all members of a clonal group. Hence, it is
also clear that efficacious antibiotic combinations against CR AB
may be highly strain-specific. To the best of our knowledge, this is
the first study that had objectively evaluated antibiotic combina-
tions for thirty-one non-isogenic CR AB isolates using the time-kill
method and the bactericidal activity as the pharmacological
measurement of efficacy. We did not use the conventional
(synergistic activity) pharmacological index as our primary
measurement of efficacy as all the test isolates were resistant to
all the antibiotics (i.e. the synergistic definition may no longer be
applicable for CR-AB organisms in an useful manner). Although
this method cannot make the results available to the clinicians in a
timely manner for individual bedside decisions, it can help narrow
down the possible alternative combinations to use for empiric
treatment while waiting for the combination testing to be
conducted for every CR AB infection.
In a similar study by Sopirala et al [21], they reported that
imipenem + colistin, or imipenem + tigecycline were effective
synergistic combinations for CR AB, while tigecycline + colistin
combination was ineffective. In contrary, polymyxins + tigecycline
was one of the promising bactericidal combination for our
Singapore CR AB isolates, while polymyxins + carbapenem
combination was not. This is likely due to the differences in the
underlying mechanisms of resistance in our CR AB, when
compared to those in Sopirala et al. Our CR-AB isolates
harboured the blaOXA-23-like and blaOXA-51-like carbapene-
mase genes, with the ISAba1 upstream of the blaOXA-23 gene
(results not shown), while the genetic determinants of resistance in
CR AB isolates in Sopirala et al revealed class 1 integrons in all of
their clones, along with OXA b-lactamases (but not extended
spectrum b-lactamases bla-PER and 294 bla-TEM) that can
hydrolyze carbapenems along with acetyltransferase genes aacA4,
aac(69)-Iad, aacC6 and phosphotransferase gene aphA1, which
impart resistance to aminoglycosides. The type of OXA b-
lactamases, however, was not reported. In addition, by selecting a
representative clone from each of the eight clonal types for
antibiotic synergy testing, Sopirala et al had assumed that the
antibiotics combination, that was synergistic and effective for the
representative clone, should also be effective for the rest in the
same clonal family. However, our findings illustrated that within a
clonal group, there may be no consensus with the types of
antibiotics combinations that could still kill effectively.
Our primary objective in this study was purely to identify
potential bactericidal antimicrobial combinations against CR-AB
in Singapore via time-kill studies. However, while Sopirala et al
aimed to determine the combination of agents which reveal in vitro
antimicrobial synergy by two different Etest methods and broth
micro-dilution checkerboard (CB) method, they also aimed to find
a method that could be easily performed in clinical microbiology
laboratory, and had the best correlation with time-kill studies by
comparing results of two different Etest and CB methods with
time-kill studies.
Overall, Sopirala’s work reinforces that different antimicrobial
combinations apply to different strains with different mechanisms
of resistance. There are many in-vitro and animal studies that
support the role of combination therapy with polymyxins against
A.baumannii. The antibiotic combinations that had been shown to
provide enhanced activity compared to any single agent include:
Table 2. 24 hour bacteria burden (log10 CFU/ml) after
exposure to individual antibiotics.
Tigecycline Polymyxin B Rifampicin
AB
strain
Baseline
inoculum Mean SD Mean SD Mean SD
8 5.22 8.53 0.04 7.13 0.05 8.07 0.04
12 5.27 8.60 0.09 5.72 0.11 7.77 0.01
16 5.23 7.72 0.02 3.50 0.07 8.69 0.03
17 5.03 3.74 0.11 9.14 0.13 3.29 0.06
23 5.35 7.94 0.04 4.94 0.12 5.99 0.13
25 5.44 6.86 0.09 5.72 0.01 7.83 0.11
28 5.30 8.08 0.11 8.61 0.04 8.73 0.03
32 5.30 3.40 0.14 5.11 0.49 7.91 0.08
41 5.38 7.99 0.01 8.04 0.01 5.56 0.11
59 5.25 8.08 0.06 5.13 0.34 9.17 0.01
60 5.36 7.97 0.09 4.02 0.00 8.46 0.01
69 5.25 8.16 0.05 5.48 0.13 8.97 0.01
70 5.26 8.33 0.02 3.12 0.08 8.60 0.02
88 5.28 7.17 0.23 4.84 0.17 6.11 0.06
91 5.20 7.14 0.17 3.00 0.06 8.58 0.07
97 5.33 6.94 0.36 4.85 0.04 5.62 0.05
98 5.54 7.72 0.23 4.31 0.15 5.59 0.01
102 5.21 6.63 0.35 5.09 0.08 8.05 0.11
104 5.16 6.84 0.08 5.05 0.06 7.70 0.11
126 5.20 8.77 0.13 5.59 0.01 5.43 0.01
128 5.42 8.71 0.12 7.86 0.00 5.82 0.01
129 5.19 8.84 0.01 4.07 0.15 8.28 0.11
138 5.38 6.77 0.13 4.40 0.06 8.36 0.04
170 5.37 7.62 0.06 5.42 0.10 8.49 0.02
174 5.26 6.35 0.05 3.57 0.10 8.24 0.08
112 5.18 7.45 0.00 4.73 0.04 7.52 0.01
8879 5.01 5.25 0.04 4.23 0.05 7.56 0.02
14101 5.40 5.38 0.23 5.71 0.13 8.33 0.13
3160 5.17 8.93 0.05 4.75 0.18 8.60 0.06
13631 5.43 7.93 0.09 5.59 0.18 8.86 0.01
48038 5.32 8.90 0.06 4.78 0.04 8.18 0.10
doi:10.1371/journal.pone.0018485.t002
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or azithromycin plus rifampicin and the triple combination of
imipenem, rifampicin and polymyxin B. In particular, polymyxins
B/E in combination with rifampicin appear most promis-
ing.[22,23,24,25,26,27,28,29] Our findings in addition to Sopir-
ala’s will lend clinical relevance in accordance to the geographical
location and help guide the use of appropriate antibiotics
combination in different parts of the world where there are
different mechanisms of resistance in CR AB.
As adequate dosing of antibiotics is pertinent in extremely
resistant infections, clinically achievable free or unbound concen-
trations from maximally possible antibiotic doses were used for all
the tested antibiotics to mimic as close as possible the killing effect
that takes place in vivo. Since it is the free or unbound protein
fraction of a drug that is pharmacologically active, all drug
exposures in the experiments were expressed as free drug
concentrations at steady state.[30] As tigecycline distributes readily
into the tissues and does not stay in serum, it is not indicated for the
treatment of bacteraemia. Hence, we utilized an achievable average
tissue concentration (that is also the CLSI breakpoint of tigecycline)
in our experiments instead of the serum concentrations.[31] Based
on the tigecycline breakpoint concentration, the results obtained
with the polymyxin B plus tigecycline combination suggested some
clinical utility in tissue infections caused by CR-AB.
Colistin heteroresistance has been reported among Acinetobacter
isolates that are still susceptible to colistin.[8,32] This is a worrying
concern as colistin or polymyxin B is increasingly been used as
monotherapy to treat micro-organisms that are reported as
susceptible to colistin/polymyxin B only. There has been a recent
report of isolates exhibiting heteroresistance from patients
previously treated with colistin.[7] Although we did not evaluate
the emergence of resistance to polymyxins in our study, our results
suggested that polymyxin B did not exhibit bactericidal activity in
the majority of our polymyxin B susceptible isolates. Combination
therapy may be the only therapeutic option to preserve the clinical
utility of the polymyxins against such resistant pathogens.
Table 3. 24 hour bacteria burden (log10 CFU/ml) after exposure to various antibiotic combinations.
Tigecycline + Rifampicin Polymyxin B + Rifampicin Polymyxin B + Tigecycline
AB strain Mean SD Mean SD Mean SD
8 6.81 0.12 0.00 0.00 5.11 0.08
12 7.19 0.01 0.00 0.00 0.00 0.00
16 4.70 0.00 3.56 0.11 0.80 1.13
17 0.00 0.00 0.00 0.00 0.65 0.92
23 4.95 0.11 4.85 0.17 4.82 0.06
25 4.73 0.00 0.00 0.00 5.01 0.01
28 5.53 0.01 3.57 0.01 4.80 0.01
32 5.41 0.08 0.00 0.00 2.31 0.15
41 4.77 0.16 4.54 0.13 5.10 0.03
59 8.67 0.00 4.10 0.05 3.24 0.04
60 6.65 0.49 5.37 0.10 0.80 1.13
69 7.64 0.06 4.10 0.11 5.08 0.08
70 6.84 0.11 4.66 0.08 4.09 0.01
88 2.42 0.05 0.00 0.00 4.90 0.05
91 0.00 0.00 0.00 0.00 4.65 0.09
97 0.00 0.00 0.00 0.00 4.25 0.06
98 0.00 0.00 0.00 0.00 4.84 0.04
102 5.35 0.04 0.00 0.00 4.86 0.22
104 4.48 0.04 4.85 0.04 4.57 0.08
126 2.60 0.00 2.48 0.00 1.60 0.42
128 5.49 0.01 2.69 0.06 0.00 0.00
129 5.93 0.00 4.73 0.04 2.28 0.18
138 5.33 0.01 3.86 0.06 4.15 0.28
170 8.29 0.01 3.79 0.10 3.66 0.00
174 5.59 0.01 4.65 0.07 4.63 0.18
112 0.00 0.00 0.00 0.00 0.00 0.00
8879 3.20 0.12 0.00 0.00 3.02 0.12
14101 4.27 0.03 5.27 0.30 7.16 0.01
3160 6.70 0.11 4.62 0.08 4.59 0.01
13631 5.91 0.10 5.44 0.06 5.94 0.06
48038 6.03 0.20 5.44 0.11 5.41 0.00
(Bactericidal combinations denoted in bold)
doi:10.1371/journal.pone.0018485.t003
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establish more clinically relevant profiles of tigecycline and
colistin/polymyxin B. This will improve the applicability of the
data in in-vitro and in-vivo models to elucidate antimicrobial
combinations against CR-AB that can potentially be utilized in a
clinically stuck situation. In-vitro combination testing of antimi-
crobial combinations using clinically relevant drug concentrations
instead of MIC-based concentrations is recommended to guide
clinicians in determining which antimicrobial combination and at
what doses are to be used as empiric therapy. Current work is in
progress to reduce the time needed to determine the useful
antibiotic combinations and make available the information to the
clinicians in a more timely fashion.
Conclusion
In summary, few treatment options are available for the
treatment of carbapenem resistant Acinetobacter baumannii. The
polymyxins remain the only agent that may be consistently active
in-vitro against them. However, polymyxin resistant isolates are
slowly emerging. Identifying novel antimicrobial combinations
with proven in-vitro activity should encompass local susceptibility
patterns as well as molecular mechanisms of resistance to provide
greater efficacy and reduce the emergence of resistance.
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